Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency

Webinar to be Held December 6, 2023 at 1:30pm ESTAUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials in greater detail. Management will be joined by three esteemed thought leaders in the field of endocrinology: Andrew Dauber, MD, Chief of Endocrinology at Children's National Medical Center, Washington, D.C.Fernando Cassorla, MD, Chief of Pediatric Endocrinology at the Institute o

Last updated : 22 Nov 2023 clock 12:04 PM

Also on site :